Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects

NCT03093103 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Vaudois as lead sponsor.

NCT NCT03093103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03093103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects
Lead sponsor
Centre Hospitalier Universitaire Vaudois
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2017
Completion date
December 31, 2018
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nephropathy